Boston Scientific Completes Acquisition of Valencia Technologies to Expand Neuromodulation Portfolio

Completing the Puzzle of Urinary Health

Boston Scientific’s Latest Acquisition Completed

On April 1 local time, Boston Scientific CorporationAnnounces Completion of the Acquisition ofValencia Technologiesacquisition of。

The acquisition agreement was announced in January this year, with specific financial terms yet to be disclosed.This is the latest major acquisition in the company's urology portfolio.

Valencia Technologies is a company that develops solutions for treating bladder dysfunction. ItsThe core product, the eCoin Implantable Tibial Nerve Stimulation (ITNS) device, received FDA approval in 2022., canTreatment of Urgent Urinary Incontinence (UUI), which are common symptoms of overactive bladder (OAB).

eCoin is a coin-sized device., placed under the skin near the ankle via minimally invasive surgery. The company designed this device for patients who have successfully undergone a percutaneous tibial nerve stimulation (PTNS) trial or for those who are intolerant of or unresponsive to more conservative treatments for urge urinary incontinence (UUI).Once implanted, the device automatically delivers intermittent stimulation to the tibial nerve to help modulate communication between the brain and the bladder.

A clinical trial demonstrated that 68% of patients experienced at least a 50% reduction in UUI episodes.

Boston Scientific has been making significant moves in the urology field. ItsAcquired Axonics for approximately $3.7 billion in 2024, directly ending its patent battle with Medtronic,Successfully Entered the Sacral Nerve Stimulation (SNS) Market。

This acquisition enables Boston Scientific to achieve technological coverage from SNS to ITNS.，The two technologies form a perfect complement.。Boston Scientific will further consolidate its leading position in the field of neuromodulation therapy.

Meghan Scanlon, President of Boston Scientific’s Urology business, stated, “The inclusion of eCoin into Boston Scientific’s portfolio will drive our expansion into the field of implantable tibial nerve stimulation, a new high-growth segment for our urology business,”ITNS Technology Complements Our Existing Pelvic Floor Health Product Line, we look forward to providing more comprehensive treatment plans for patients throughout the entire course of their disease.”

A spokesperson for Boston Scientific stated,Acquisition of Valencia Technologies Further Enhances the Company’s Pelvic Health Product Portfolio, Implantable Tibial Nerve Stimulation (ITNS) is a high-growth niche segment,Incorporating ITNS fills the company’s previous product gap in this field.. This strategic expansion will significantly enrich the clinical treatment options available to physicians for patients with pelvic diseases.

In Q3 2025, Boston Scientific’s urology business reported revenue of $682 million, a year-over-year increase of 28.1%, with full-year 2025 growth reaching 23.1%, demonstrating strong momentum. According to recent disclosures by Boston Scientific,The strengthening of the sacral neuromodulation business will also directly drive the recovery of the overall business.

02

Aggressive Multi-Sector Expansion

Boston Scientific Launches "Aggressive Acquisition" Mode

In recent years, Boston Scientific has been expanding into multiple sectors through an aggressive acquisition strategy.

In March 2025, acquired the remaining equity of SoniVie for $360 million, further strengthening its position in the RDN field;

In April 2025, acquired Bolt Medical to enter the IVL (intravascular lithotripsy) market;

In October 2025, the acquisition of Nalu Medical was finalized to complete the chronic pain management portfolio and achieve full coverage of the neuromodulation product matrix.

In January 2026, Boston Scientific announced two major acquisitions in succession. In addition to acquiring Valencia Technologies, it also spent hundreds of billions (RMB) to acquire the medical technology company Penumbra, to further enhance its portfolio in cardiology and neurovascular fields.

It is not difficult to see that Boston Scientific’s M&A focus has consistently remained on the “golden tracks” of the healthcare sector.

With the growing number of elderly patients, urinary incontinence or mobility impairments caused by stroke, dementia, diabetes, prostate diseases, and bladder disorders have created substantial market demand for treatments related to urinary incontinence.

According to data from Johns Hopkins Medicine,More than 25 million adults in the United States are affected by urinary incontinence to varying degrees, with women over the age of 50 being the most commonly affected group.

The global market for urinary incontinence treatment devices was valued at approximately USD 3.1–3.8 billion in 2023 and is projected to reach USD 6.0–6.5 billion by 2032, with a compound annual growth rate (CAGR) of 8%–11%. Among these, sacral nerve stimulation (SNS), as the mainstream neuromodulation technology, had a global market size of approximately USD 1.6 billion in 2023. It is expected to achieve a CAGR exceeding 11% before 2030, with an even higher growth rate in the Asia-Pacific region (approximately 13%).

It is understood that,Both the US and European healthcare systems have included implantable medical devices for treating urinary and fecal incontinence within their coverage scopes.。Boston Scientific’s 2024 acquisition of Axonics has secured mainstream insurance reimbursement coverage for its related treatment solutions., including Medicare, which serves individuals aged 65 and older as well as people with disabilities, may also cover this therapy.

Boston Scientific’s “acquisition spree” is not blind expansion, but rather a rational decision based on future high-growth markets and rigorous financial analysis.

Leveraging M&A to build a technological moat has become a common strategy among medical device giants. Whether integration can deliver synergistic value greater than the sum of its parts (1+1>2) remains uncertain, with both opportunities and variables coexisting in the sector’s future.

END